Objective: To compare the effectiveness of glyburide and insulin for the treatment of Gestational diabetes mellitus (GDM) in women who had OGCT X200 mg/dl and fasting hyperglycemia.
Introduction
Gestational diabetes mellitus (GDM) complicates 2 to 5% of pregnancies and is associated with significant maternal and neonatal morbidity and mortality. 1 GDM is diagnosed by the finding of two abnormal values on a 3 h oral glucose tolerance test (OGTT) after a patient is initially screened by a 50 g oral glucose challenge test (OGCT). 2 However, a subset of gestational diabetics have an OGCT>200 mg/dl and fasting hyperglycemia. This subset of the population is thought to represent a group of patients with increased insulin resistance and even pre-existing diabetes mellitus. 2 Over 80% of women with an OGCT>200 mg/dl alone will be diagnosed with GDM and 25% of them will require pharmacologic treatment. 3 In addition, although fasting plasma glucose (FPG) is a poor screening test for GDM, a cutoff of 105 mg/dl has greater than 99% specificity and 65% of these patients will require insulin. [4] [5] [6] In 1999 the California Diabetes and Pregnancy Program, Sweet Success, adopted a protocol for diagnosing GDM based on OGCT>200 mg/dl and FPG>105 mg/dl. 7 Using this protocol, there is the benefit of avoiding extreme hyperglycemia as a result of the OGTT. Kaiser Permanente Northern California (KPNC) adopted similar guidelines for diagnosing GDM.
In the United States, traditional therapy for women with GDM who fail diet therapy has been insulin. A randomized trial by Langer et al. and a retrospective study by Jacobson et al. concluded that glyburide was an effective alternative to insulin for the treatment of gestational diabetes, 8, 9 although both studies were underpowered to detect differences in some of the more rare neonatal outcomes. Despite limited clinical studies, recent expert opinion has suggested glyburide as an alternative first choice for GDM and a survey in 2003 found that 13% of obstetrician-gynecologists begin with glyburide for patients requiring therapy beyond diet.
10,11 KPNC adopted guidelines for the use of glyburide for the treatment of GDM in February 2001. The aim of this study is to report our experience with the use of glyburide for treatment of GDM diagnosed by markedly elevated OGCT and fasting hyperglycemia in a large managed care organization.
Materials and methods
We performed a retrospective study among women treated for GDM who had a 50 g OGCT X200 mg/dl and FPG X105 mg/dl. We compared women requiring insulin in the 2-year period before the introduction of glyburide to women treated with glyburide in the 2 years after its introduction in KPNC. KPNC is a prepaid group-model managed care organization that provides comprehensive medical services to over three million members in a 14 county region, serving approximately 30% of the population in the area.
Eligibility for the study was limited to women with singleton pregnancies diagnosed with GDM at less than 34 weeks between January 1999 and December 2002. KPNC guidelines for the diagnosis of GDM included an abnormal 50 g OGCTX140 mg/dl and a diagnostic 3 h OGTT using National Diabetes Data Group (NDDG) criteria (fastingX105, 1 hX190, 2 hX165, 3 hX145 mg/dl). 12 However for OGCTX200 mg/dl, providers could either perform a 3-h OGTT or first obtain a FPG. Inclusion criteria was limited only to women with an OGCTX200 mg/dl and a pretreatment FPGX105 mg/dl. Two primary groups were defined: insulin group diagnosed with GDM in 1999 to 2000 and glyburide group diagnosed with GDM in 2001 to 2002. The decision to use either glyburide or insulin from 2001 to 2002 was at the discretion of the treating physician. Treatment failure with glyburide was defined as beginning insulin therapy after starting glyburide for any reason. Glyburide treatment failures were analyzed in the glyburide group, in a similar fashion to an intention-to-treat analysis. Patients received care at 23 clinics and delivered at 11 hospitals. Forty-six women (30 insulin; 16 glyburide) who met the above diagnostic criteria were reported previously in a study of the same KPNC population that used the more traditional diagnostic criteria for GDM. 9 General management of patients diagnosed with GDM included: nutritional counseling regarding a diabetic diet during pregnancy with three meals and three snacks and instruction on self-monitoring capillary blood glucose with a glucometer. Patients were advised to monitor blood sugars four times a day: fasting and either 1 or 2 h post-prandials (per individual provider preference) for breakfast, lunch and dinner. Specific goals for plasma fasting, 1 h and 2 h post-prandials were 100, 155 and 130 mg/dl, respectively. Reviews of clinical information databases and charts were performed to obtain demographic data. Information on previous history of GDM and previous macrosomic delivery were missing in over 60% of the patients and therefore were not reported. BMI was calculated using first documented weight during pregnancy. Preterm delivery was defined as delivery <37 weeks gestational age. According to the gestational age-specific weight distribution of the study population, infants were considered large for gestational age (LGA), or small for gestational age (SGA), if their birth weight exceeded, or was below, the 90th or 10th percentiles, respectively, using KPNC-derived algorithms. Macrosomia was defined as birth weightX4000 g.
Neonatal hyperbilirubinemia was defined as a total bilirubin X12 mg/dl within the first 7 days of birth. Neonatal polycythemia was defined as hematocrit X60% and neonatal hypocalcemia was defined as calcium <7.0 mg/dl within 3 days of birth. Decision to check any laboratory value was made by local providers based on clinical indications. An Admission, Discharge, Transfer database with all KPNC hospitalizations was searched using appropriate International Classification of Diseases, version 9, clinical Modification codes for the following outcomes: neonatal hypoglycemia, pre-eclampsia, congenital anomalies, birth injury, neonatal exchange transfusions and phototherapy.
The KPNC Neonatal Minimum Data Set (NMDS) database was used to obtain data on neonatal intensive care unit (NICU) admissions including length of stay and need for oxygen/assisted ventilation. NMDS defines oxygen/assisted ventilation as a baby receiving supplemental oxygen (O 2 at 21% for X1 h) or requiring ventilation during hospitalization.
Statistical methods to assess bivariate differences included Student's t-test for difference of means, w 2 test (or Fisher's exact test where appropriate) for difference of proportions and for interval level variables found not to be normally distributed by the Shapiro-Wilk's test at P<0.01, the non-parametric Wilcoxon's two-sample test. 13 Multivariable logistic regression was used to compute adjusted odds ratios (ORs) and 95% confidence intervals controlling for the following variables suggested by bivariate analyses: age, BMI and race/ethnicity. The Kaiser Permanente Institutional Review Board for the Protection of Human Subjects approved this study in June 2005.
Results
In the four-year study period, 147 women fulfilled inclusion criteria. During 1999 to 2000, 78 women were diagnosed and treated with insulin (30 reported previously). In 2001 to 2002, after the introduction of glyburide, 69 women were diagnosed, of whom, 44 (64%) were treated with glyburide (16 reported previously) and 25 (36%) received insulin. Table 1 shows the characteristics of the insulin and glyburide groups. The two groups were generally similar including mean OGCT (230 vs 223 mg/dl, P ¼ 0.07) and mean fasting glucose (120 vs 119 mg/dl, P ¼ 0.45). However, women in the insulin group were younger (31.5 vs 35.2 years, P<0.001) and had a higher mean BMI (32.4 vs 29.1 kg/m 2 , P ¼ 0.003) compared to the glyburide group. Maximum daily insulin dose was available for 74 women: mean 47.1±36.8 units (median 74, range 1 to 242). Maximum daily glyburide dose was available for 40 women: mean 8.2±5.6 mg (median 5, range 2.5 to 20). Table 2 shows the maternal and neonatal outcomes of the insulin and glyburide groups. There were no significant differences for most outcomes, however, neonates in the glyburide group had a higher incidence of hypoglycemia (34%, 14%, P ¼ 0.01) and anomalies (9%, 0%, P ¼ 0.02). There was no statistically significant difference in birth weight of term infants between the insulin and glyburide groups (3599±476, 3673±586, P ¼ 0.53) or in the rate of cesarean section between nulliparous (47%, 39%, P ¼ 0.6) or parous (32%, 48%, P ¼ 0.15) women in the two treatment groups. Of the 15 neonates in the glyburide group with hypoglycemia, two women had failed glyburide and had been switched to insulin before delivery. Among the remaining 13, the mean dose of glyburide was 7.9±5.2 mg/dl and none were on the maximum 20 mg/dl.
Multivariable logistic regression analysis was performed controlling for age and BMI, variables shown to differ between the two groups in the bivariate analysis. Although there was no overall difference in race/ethnicity, because a much higher proportion of the glyburide group self-identified as Asian we decided to also control for race/ethnicity. When controlling for potential confounders, adjusted ORs were significant only for macrosomia after controlling for variables shown to differ between the two groups (Table 3) . Similar results were obtained when multivariable analysis included only term deliveries (data not shown). No differences were noted for LGA, SGA, polycythemia or phototherapy; however, our statistical models for these outcomes did not provide reliable results so statistics for these variables were not included in Table 3 . There were no neonatal deaths, lethal anomalies, exchange transfusions, or fetal demise in either group. The glyburide group had four infants with anomalies, (patent ductus arteriosus (PDA); ventricular septal defect (VSD); inguinal hernias; one infant with PDA, atrial septal defect (ASD), intestinal atresia and spine anomaly). There were no anomalies in the insulin group. One neonate in the insulin group had a birth injury (brachial plexus injury). Two neonates in the glyburide group had birth injuries: one brachial plexus injury and one clavicle fracture.
Seven (16%) women failed glyburide and were switched to insulin (all were analyzed with the glyburide group similar to an intention-to -treat analysis). These women had the following characteristics (means): BMI 28.4 kg/m 2 , fasting glucose 113.6 mg/dl and 19.1 lb pregnancy weight gain. Insulin was started at a mean gestational age of 29.6±5.2 weeks and reached a mean insulin dose of 54.4±24.4 U/day (range 33 to 92). Mean birth weight was 3899 g 
Discussion
Women with GDM who have a markedly elevated OGCT and fasting hyperglycemia represent a subgroup of gestational diabetics with increased insulin resistance. 2 Our restrospective study suggests that glyburide may not be as effective as insulin for this subset of women with GDM, with an increased risk of macrosomia in the glyburide group noted in multivariable analysis as well as a trend towards an increased risk of neonatal hypoglycemia. We found no differences in mode of delivery, pre-eclampsia and most neonatal metabolic complications. Neonatal birth weights and rates of NICU admissions and the length of stay were also similar between the groups. However, given our small sample size type II error cannot be excluded. In our study, 16% of those treated with glyburide failed the therapy and this is comparable to recent published reports. 9, [14] [15] [16] [17] [18] The glyburide group had a higher proportion of neonates diagnosed with hypoglycemia in our bivariate analysis. This finding did not remain statistically significant in a multivariable model after controlling for age, BMI and ethnicity. Neonatal hypoglycemia may be a result of poor glycemic control. 19 The patients in our study are a subset of women with increased insulin resistance and may represent a group of diabetics in whom euglycemia is difficult to achieve. In other studies that used the traditional diagnosis of GDM, glyburide was not found to be associated with neonatal hypoglycemia. 8-9,14 -18 The theoretical possibility of glyburide crossing the placenta and directly leading to neonatal hypoglycemia may be of concern but in one study, 8 glyburide was not found to cross the placenta in significant concentrations. Finally, in our study the diagnosis of neonatal hypoglycemia was based upon ICD-9 codes instead of strict laboratory criteria. Thus, coding error may lead to misclassification bias. Further, ascertainment bias is a potential confounder because it is unknown whether neonatologists would be more or less likely to diagnose and/or code for certain conditions based on knowledge of the maternal treatment status.
There was a higher rate of congenital anomalies in the glyburide group. Most of the anomalies were minor with the exception of one infant with PDA, ASD, intestinal atresia and spine anomaly. The mean gestational age for starting glyburide was 27 weeks, well beyond organogenesis. The patients in our study are a subset of women with increased insulin resistance and this finding may also reflect a higher incidence of undiagnosed type II diabetes with poor control at conception in this cohort.
Logistic regression analysis showed an increased risk of macrosomia in the glyburide treated group. Although this model controlled for potential confounders such as age, ethnicity and BMI, it did not control for other potential confounders such as previous history of macrosomia. In a secondary analysis of their original study, Langer et al. compared adverse pregnancy outcomes in gestational diabetics treated with insulin or glyburide at differing disease severities and found no differences in outcomes. Furthermore, in their analysis severity of GDM (characterized by fasting plasma and mean blood glucose determinations), weight gain and previous macrosomia were the only significant contributors to adverse outcomes. 20 The increased risk of macrosomia may also be a reflection of poor glycemic control. Although no differences in other measures of glycemic control were noted between the groups, a type II error cannot be excluded owing to the small sample size of our study.
Although our study is the first to evaluate the efficacy of glyburide in a cohort of women with particularly increased insulin resistance, the observational design and the small sample size of our study may lend itself to inherent biases and possibly type II error. We could not control for potential biases from possible inconsistencies in GDM management between the 23 treatment facilities. The racial/ethnic differences in our population were noted to shift over the time period of our study with an increase in the Asian population. Additionally, comparison of our groups suggests a selection bias of older women who had lower BMIs to receive glyburide. Furthermore, although we attempted to control for potential confounding variables, we did not have information on some possible confounders such as previous delivery of a macrosomic infant or history of GDM. A significantly larger randomized controlled trial is needed to overcome the inherent biases of the observational study design as well as the risks of a type II error in this small study.
In women with GDM who had a markedly elevated OGCT and fasting hyperglycemia, glyburide may not be as effective as insulin at preventing macrosomia. Neonatal metabolic complications of GDM, particularly hypoglycemia, and other rare neonatal complications of interest should be evaluated in larger prospective studies in the neonates of mothers treated with glyburide. Further studies should also aim to address the factors that contribute to glyburide failures as well as what the optimal dosing of glyburide should be.
